BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, November 4, 2024
See today's BioWorld MedTech
Home
» Robocath raises $43M series C funding to accelerate distribution of its robotic PCI platform throughout Asia
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Robocath raises $43M series C funding to accelerate distribution of its robotic PCI platform throughout Asia
June 8, 2020
By
Bernard Banga
No Comments
PARIS – Robocath SAS, of Rouen, France, has secured a new $43 million funding round to boost roll-out of its R-One robotic system for treating vascular disease. This series C funding was led by Hong Kong-based Microport Scientific Corp.
BioWorld MedTech
Financings
Cardiovascular
Series C
Robotic surgery
Europe